Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech)(Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech))

概要

基本信息

药物类型

预防性疫苗、多价疫苗

别名-

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染呼吸系统疾病

在研适应症-

非在研适应症

流感病毒感染

原研机构

Folia Biotech, Inc.

在研机构-

非在研机构

Folia Biotech, Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的临床试验

JPRN-jRCTs041230032

/ Recruiting临床1期IIT

Safety study of Plasma-activated Lactate Ringer's Solution (PAL) for application on human normal skin - Safety study of PAL for application on human skin

开始日期2023-06-08

申办/合作机构-

NCT02188810

/ Unknown status临床1期

A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults.

This is a phase 1, research study is looking at the safety and acceptability of a new vaccine adjuvant (immune booster) called PAL when combined with the seasonal flu vaccine (Fluviral) to test the safety and effectiveness of new vaccines and medications on healthy volunteers.
The study will enroll approximately 48 healthy adult participants, and occur over 3 years. In the first six months/180 days of the study participants will have visits to the study site during which safety and immunogenicity outcomes will be measured. From Day 181 to Year 3, participants will be contacted by telephone or email to collect information on any adverse events.

开始日期2014-04-01

申办/合作机构

Folia Biotech, Inc.

100 项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的临床结果

登录后查看更多信息

100 项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的转化医学

登录后查看更多信息

100 项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的专利（医药）

登录后查看更多信息

485

项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的文献（医药）

2025-03-01·Journal of Hazardous Materials

Potential ecological risk of microplastics contamination to environment in protect area lakes

Article

作者: Honghui, Lin ; Zao, Yang ; Xin, Liu ; Xintong, Mei ; Bo, Zhong ; Xiaofeng, Wang ; Naying, Li ; Yixin, He

Microplastics (MPs) in freshwater have been extensively studied on a global scale. However, a deeper understanding is still required regarding the occurrence characteristics and ecological risks of MPs in protected area lakes(PAL). Here, the study investigated MPs pollution in PAL, outside protected areas lakes (OPAL), and ponds (OPAP) in the eastern Qinghai-Tibetan Plateau, and a comprehensive analysis was conducted comparing lakes or ponds from different income regions. The results showed that PAL has a single source of contamination, while OPAL and OPAP exhibited more diverse MP sources. The surface of all samples showed significant physicochemical changes like oxygen-containing functional groups and potential signs of biodegradation. Microbiome analysis identified potential plastic-degrading bacteria on MPs, which varied by polymer type. Ecological risk assessment revealed that OPAL and OPAP face higher ecological risks, particularly from polymers like PVC and PC, while PAL has low risk. However, we should also consider the environmental changes over the past 100 years of history in this region and emphasize the environmental health of PAL. Notably, MPs pollution is more severe in lower-middle-income regions, highlighting the urgent need for stricter controls.

2025-02-01·Molecular Neurobiology

Palmatine Ameliorates Motor Deficits and Dopaminergic Neuron Loss by Regulating NLRP3 Inflammasome through Mitophagy in Parkinson's Disease Model Mice

Article

作者: Zhang, Yuxiao ; Yang, Shuda ; Zhao, Kunying ; Dong, Junfang ; Zhao, Jindong ; Hu, Weiyan ; Xiang, Lirong ; Wang, Ji ; Wu, Shangpeng

AbstractNLRP3 inflammasomes-mediated proinflammatory response and mitochondrial dysfunction play a critical role in the etiology and pathogenesis of Parkinson's disease. Negative regulation of NLRP3 inflammasome activation through mitophagy may be an important strategy to control NLRP3 inflammasome-mediated proinflammatory responses. Palmatine (PAL), an isoquinoline alkaloid found in various of plants, has potent pharmacological effects such as anti-inflammatory and anti-oxidation. However, the specific role of PAL in the pathology of Parkinson's disease remains unclear. In this study, we found that treatment with PAL improved motor deficits and reduced the loss of dopaminergic neurons in MPTP mice. Further results showed that PAL promoted mitophagy and inhibited the proinflammatory response mediated by NLRP3 inflammasomes. In addition, chloroquine (CQ, mitophagy inhibitor) attenuated the ameliorative effects of PAL on the motor deficits and dopaminergic neuron damage, as well as the inhibitory effect of PAL on NLRP3 inflammasome. Collectively, these results provide strong evidence that PAL ameliorates motor deficits and dopaminergic neuron death in Parkinson’s disease, and the mechanism may be related to its inhibition of NLRP3 inflammasome activation via promoting mitophagy.

2025-02-01·Journal of Controlled Release

Self-assembled natural triterpenoids for the delivery of cyclin-dependent kinase 4/6 inhibitors to enhance cancer chemoimmunotherapy

Article

作者: Zhang, Yongbo ; Zhao, Shuang ; Cheng, Jianjun ; Du, Guanhua ; Lian, Yajie ; Lu, Xin ; Shi, Jiahua ; Wang, Jiacheng ; Liu, Hongjun ; Zhou, Conglei

Immunogenic cell death (ICD) has recently emerged as a promising strategy in reinforcing anti-PD-L1 blockade immunotherapy of triple-negative breast cancer (TNBC). The CDK4/6 inhibitor palbociclib (PAL), as a clinical star medicine targeting the cell cycle machinery, is an ideal candidate for fabricating a highly efficient ICD inducer for TNBC chemoimmunotherapy. However, the frequently observed chemoresistance and clinical adverse effects, as well as significant antagonistic effects when co-administered with certain chemotherapeutics, have seriously restricted the efficiency of PAL and the feasibility of combination strategies. Herein, we screened and identified six self-assembled natural pentacyclic triterpenoid (PT) molecules that can serve as competent co-administration nanoplatforms for the synergistic or combined delivery of PAL. Analysis of two representative PT-PAL nano-assemblies validated that PT-mediated co-assembly enhances the cytotoxicity and synergy of PAL by inhibiting the PI3K/AKT/mTOR signaling pathway, rather than directly targeting CDK4/6 proteins. Importantly, the PAL nanoassemblies exhibited multiple favorable therapeutic features and stronger accumulative ICD induction, ensuring highly efficient synergistic anti-PD-L1 chemoimmunotherapy by simultaneously facilitating T-cell immune response and reversing the immunosuppressive tumor microenvironment. This study offers possibilities for improving the anticancer efficacy of CDK4/6 inhibitors and potential avenues for clinical applications of chemoimmunotherapy in treating TNBC.

100 项与 Trivalent influenza vaccine adjuvanted with PAL(Folia Biotech) 相关的药物交易

登录后查看更多信息